BR9811362A - Composto - Google Patents
CompostoInfo
- Publication number
- BR9811362A BR9811362A BR9811362-3A BR9811362A BR9811362A BR 9811362 A BR9811362 A BR 9811362A BR 9811362 A BR9811362 A BR 9811362A BR 9811362 A BR9811362 A BR 9811362A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- agonists
- antagonists
- compounds
- unsubstituted alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000556 agonist Substances 0.000 abstract 4
- 102000027484 GABAA receptors Human genes 0.000 abstract 2
- 108091008681 GABAA receptors Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTO". A presente invenção abrange estruturas da Fórmula (I) ou seus sais não tóxicos farmaceuticamente aceitáveis em que: X é hidrogênio, halogênio, alquila substituída ou não substituída, alcóxi substituído ou não substituído ou amino; e Y é alquila, arila ou heteroarila substituídas ou não substituídas, cujos compostos são agonistas, antagonistas ou agonistas inversos altamente seletivos quanto aos receptores cerebrais GABAa ou pró-medicamentos de agonistas, antagonistas ou agonistas inversos para os receptores cerebrais GABAa. Estes compostos são utilizáveis no diagnóstico e no tratamento da ansiedade, Síndrome de Down, distúrbios do sono, cognitivos e de convulsão e dose excessiva com medicamentos de benzodiazepina e para realce da agilidade.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91818097A | 1997-08-25 | 1997-08-25 | |
| PCT/US1998/017513 WO1999010347A1 (en) | 1997-08-25 | 1998-08-24 | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9811362A true BR9811362A (pt) | 2000-08-22 |
Family
ID=25439933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9811362-3A BR9811362A (pt) | 1997-08-25 | 1998-08-24 | Composto |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1007526A1 (pt) |
| JP (1) | JP2001514181A (pt) |
| KR (1) | KR20010023313A (pt) |
| CN (1) | CN1268136A (pt) |
| AP (1) | AP2000001742A0 (pt) |
| AU (1) | AU753800B2 (pt) |
| BG (1) | BG104192A (pt) |
| BR (1) | BR9811362A (pt) |
| CA (1) | CA2301599C (pt) |
| EG (1) | EG21717A (pt) |
| HU (1) | HUP0003258A3 (pt) |
| IL (1) | IL134291A0 (pt) |
| IS (1) | IS5382A (pt) |
| LV (1) | LV12539B (pt) |
| NO (1) | NO20000822L (pt) |
| NZ (1) | NZ502548A (pt) |
| OA (1) | OA11293A (pt) |
| PE (1) | PE130999A1 (pt) |
| PL (1) | PL338783A1 (pt) |
| SI (1) | SI20270A (pt) |
| SK (1) | SK2162000A3 (pt) |
| TW (1) | TW574221B (pt) |
| WO (1) | WO1999010347A1 (pt) |
| YU (1) | YU10500A (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1177177B1 (en) * | 1999-05-06 | 2005-02-23 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
| AU5289600A (en) * | 1999-05-25 | 2000-12-12 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
| US6562822B2 (en) | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| HUP0302367A2 (hu) | 2000-10-12 | 2003-11-28 | Merck & Co., Inc. | HIV Integráz inhibitorokként hasznos aza- és poliazanaftalenil-karboxamidok, ezeket tartalmazó gyógyszerkészítmények |
| WO2002030426A1 (en) | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| US6841558B2 (en) | 2000-10-12 | 2005-01-11 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors |
| US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| NZ527397A (en) * | 2001-03-01 | 2005-05-27 | Pfizer Prod Inc | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders |
| AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
| CA2472372C (en) | 2002-01-17 | 2010-08-17 | Melissa Egbertson | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| JP4494020B2 (ja) | 2002-03-15 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖインテグラーゼ阻害剤として有用なｎ−（置換ベンジル）−８−ヒドロキシ−１，６−ナフチリジン−７−カルボキサミド |
| WO2004106336A1 (en) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides |
| WO2004106334A2 (en) * | 2003-05-28 | 2004-12-09 | Pfizer Products Inc. | Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation |
| EP2540722B1 (en) * | 2006-10-16 | 2016-06-08 | Bionomics Limited | Novel anxiolytic compounds |
| EP2083811B1 (en) * | 2006-11-22 | 2016-10-26 | Clinical Research Associates, LLC | Methods of treating down's syndrome, fragile x syndrome and autism |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR204813A1 (es) * | 1972-05-08 | 1976-03-05 | Yamanouchi Pharma Co Ltd | Proceso para la preparacion de derivados de ampilicina |
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| DD295360A5 (de) * | 1987-07-03 | 1991-10-31 | Akad Wissenschaften | Verfahren zur Herstellung von aktivierten Carbonsäureestern |
| DD279887A1 (de) * | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika |
| DD279875A1 (de) * | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von aktivierten carbonsaeureestern |
| JPS6461461A (en) * | 1987-09-01 | 1989-03-08 | Otsuka Pharma Co Ltd | Benzohetero ring derivative |
-
1998
- 1998-08-24 SK SK216-2000A patent/SK2162000A3/sk unknown
- 1998-08-24 NZ NZ502548A patent/NZ502548A/en unknown
- 1998-08-24 CA CA002301599A patent/CA2301599C/en not_active Expired - Fee Related
- 1998-08-24 AU AU91173/98A patent/AU753800B2/en not_active Ceased
- 1998-08-24 KR KR1020007001948A patent/KR20010023313A/ko not_active Withdrawn
- 1998-08-24 YU YU10500A patent/YU10500A/sh unknown
- 1998-08-24 BR BR9811362-3A patent/BR9811362A/pt not_active Application Discontinuation
- 1998-08-24 HU HU0003258A patent/HUP0003258A3/hu unknown
- 1998-08-24 SI SI9820055A patent/SI20270A/sl unknown
- 1998-08-24 EP EP98943352A patent/EP1007526A1/en not_active Withdrawn
- 1998-08-24 JP JP2000507675A patent/JP2001514181A/ja active Pending
- 1998-08-24 WO PCT/US1998/017513 patent/WO1999010347A1/en not_active Ceased
- 1998-08-24 IL IL13429198A patent/IL134291A0/xx unknown
- 1998-08-24 CN CN98808578A patent/CN1268136A/zh active Pending
- 1998-08-24 PL PL98338783A patent/PL338783A1/xx unknown
- 1998-09-29 EG EG118098A patent/EG21717A/xx active
- 1998-10-23 TW TW87117597A patent/TW574221B/zh active
- 1998-11-13 PE PE1998001100A patent/PE130999A1/es not_active Application Discontinuation
-
2000
- 2000-02-01 AP APAP/P/2000/001742A patent/AP2000001742A0/en unknown
- 2000-02-18 OA OA1200000044A patent/OA11293A/en unknown
- 2000-02-18 NO NO20000822A patent/NO20000822L/no not_active Application Discontinuation
- 2000-02-22 IS IS5382A patent/IS5382A/is unknown
- 2000-02-25 BG BG104192A patent/BG104192A/xx unknown
- 2000-03-16 LV LVP-00-29A patent/LV12539B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU9117398A (en) | 1999-03-16 |
| NO20000822L (no) | 2000-04-13 |
| BG104192A (en) | 2001-05-31 |
| CN1268136A (zh) | 2000-09-27 |
| AU753800B2 (en) | 2002-10-31 |
| KR20010023313A (ko) | 2001-03-26 |
| TW574221B (en) | 2004-02-01 |
| IL134291A0 (en) | 2001-04-30 |
| PL338783A1 (en) | 2000-11-20 |
| SK2162000A3 (en) | 2001-03-12 |
| EP1007526A1 (en) | 2000-06-14 |
| CA2301599C (en) | 2003-03-25 |
| HUP0003258A2 (en) | 2001-03-28 |
| JP2001514181A (ja) | 2001-09-11 |
| YU10500A (sh) | 2002-10-18 |
| CA2301599A1 (en) | 1999-03-04 |
| AP2000001742A0 (en) | 2000-02-24 |
| WO1999010347A1 (en) | 1999-03-04 |
| LV12539A (en) | 2000-10-20 |
| NO20000822D0 (no) | 2000-02-18 |
| EG21717A (en) | 2002-02-27 |
| PE130999A1 (es) | 1999-12-16 |
| HUP0003258A3 (en) | 2001-05-28 |
| IS5382A (is) | 2000-02-22 |
| OA11293A (en) | 2002-11-19 |
| LV12539B (en) | 2001-01-20 |
| NZ502548A (en) | 2002-06-28 |
| SI20270A (sl) | 2000-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9811362A (pt) | Composto | |
| DK0555391T3 (da) | Visse imidazoquinoxaliner; en ny klasse GABA-receptorligander i hjernen | |
| CA2175204A1 (en) | Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands | |
| BR9608048A (pt) | Compostos de benzimidazol, composições farmacêuticas contendo os compostos e seu uso. | |
| ATE277927T1 (de) | Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren | |
| BR0113300A (pt) | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, método para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, uso de um composto ou um sal, é, métodos para localização dos receptores de gabaa em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina a um receptor de gabaa, e para a alteração da atividade de transdutora de sinal dos receptores de gabaa | |
| NO952687D0 (no) | Tiazolidinderivater, deres fremstilling samt medikamenter inneholdende forbindelsene | |
| NO306464B1 (no) | Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter | |
| BR9608056A (pt) | Compostos de benzimidazol, composições farmacêuticas contendo os compostos e sua utilização. | |
| BR0214455A (pt) | Derivados benzotiazol | |
| BR0013314A (pt) | Composto quìmico de derivados de indolina, seu uso e método de preparação, método de tratamento, composição farmacêutica e método de fabricação de uma composição que o contém | |
| WO2002000623A3 (en) | Aryl fused substituted 4-oxy-pyridines | |
| BR0013311A (pt) | Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor | |
| BR0010573A (pt) | Métodos de tratamento ou prevenção, em um paciente, de ansiedade, de um estado convulsivo, de espasticidade ou espasmos musculares agudos, de um distútbios afetivo de um comportamento agressivo, de vìcio de drogas ou álcool, de nìveis de hormÈnio no plasma anormais, de distúrbio do sono, de uma doença ou condição ou sintoma da mesma, em um paciente afetado pela modulação de um ou mais dos receptores de benzodiazepina centrais ou periféricos, composição farmacêutica, forma de dosagem individual de n-desmetilzopiclona, métodos para preparar n-desmetilzopiclona, e racêmica, para preparar (+), e (-) n-desmetil zopiclona, e, para aumentar a pureza óptica de zopiclona ou desmetilzopiclona | |
| BR9908321A (pt) | Composto | |
| BRPI0411285A (pt) | composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios | |
| BR9902651A (pt) | Derivados de diaza-espiro[3,5]nonano | |
| BRPI0410613A (pt) | preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano | |
| PT1011679E (pt) | Utilizacao de 8-nitro-2,3,4,5-tetra-hidro-1h-3-benzazepinas para o fabrico de uma composicao farmacetica para o tratamento de doencas do sono | |
| BR0010213A (pt) | Derivados de ciclocarbamato como moduladores de receptor de progesterona | |
| ATE300539T1 (de) | Oxo-pyridoimidazol-carboxamide: gaba-rezeptor- liganden im gehirn | |
| BR9807701A (pt) | Derivados de 4-aminoalcóxi-1h-benzimidazol, seu preparo e seu uso como agonistas do auto-receptor (d2) de dopamina | |
| CA2249562A1 (en) | Certain fused pyrrolecarboxamides as gaba brain receptor ligands | |
| ES2188155T3 (es) | N-ariloxietilindolilalquilaminas para el tratamiento de la depresion. | |
| BR9807840A (pt) | Derivados de 4-aminoalcóxi-1,3-dihidrobenzoimidazol-2-tionas, sua preparação e seu uso como agonistas de auto-receptor de dopamina (d2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |